They also demonstrated the reducing effect of miglustat, a glucosylceramide synthase inhibitor, on GPNMB protein and mRNA expression in a U18666A-induced NPC phenotype model using RAW264.7 murine macrophage cells. This evidence concerns the gene GPNMB and nasopharyngeal carcinoma.